Share
.webp)
.webp)
.webp)
.webp)
Larry Lockwood
ElevateBio, a technology-driven company dedicated to advancing life-transforming genetic medicines, has appointed Larry Lockwood, Ph.D., as Chief Commercial Officer.
Dr. Lockwood brings over two decades of leadership experience and a strong record of building and scaling commercial organizations, driving revenue growth, and forging global partnerships in the life sciences sector.
In his new role, Dr. Lockwood will oversee ElevateBio’s commercial strategy, focusing on accelerating growth across its businesses. He will expand partnerships at BaseCamp, ElevateBio’s state-of-the-art cGMP manufacturing arm, while also advancing monetization strategies for Life Edit, the Company’s gene editing and R&D platform.
With extensive expertise in transforming advanced manufacturing solutions into long-term commercial contracts, he is well-positioned to strengthen ElevateBio’s market presence in the rapidly evolving genetic medicine landscape.
Before joining ElevateBio, Dr. Lockwood served as Global Head of CDMO Strategy at Aldevron, part of Danaher Life Sciences. There, he spearheaded go-to-market strategy development and built strategic alliances with CDMOs worldwide, significantly enhancing client engagement and service delivery. His earlier roles at Aldevron included Vice President, Key Accounts and Vice President, Sales, where he played a pivotal role in advancing the company’s global reach. He has also held leadership positions at RoosterBio Inc., Horizon Discovery Ltd., Lonza Biologics Inc., and AMRI Inc.
Dr. Lockwood holds a Ph.D. in Organic Chemistry from Rensselaer Polytechnic Institute and a B.S. in Chemistry from Towson State University.
